JP2019524111A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524111A5
JP2019524111A5 JP2019503341A JP2019503341A JP2019524111A5 JP 2019524111 A5 JP2019524111 A5 JP 2019524111A5 JP 2019503341 A JP2019503341 A JP 2019503341A JP 2019503341 A JP2019503341 A JP 2019503341A JP 2019524111 A5 JP2019524111 A5 JP 2019524111A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
chain variable
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503341A
Other languages
English (en)
Japanese (ja)
Other versions
JP7082967B2 (ja
JP2019524111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/043504 external-priority patent/WO2018018039A2/en
Publication of JP2019524111A publication Critical patent/JP2019524111A/ja
Publication of JP2019524111A5 publication Critical patent/JP2019524111A5/ja
Application granted granted Critical
Publication of JP7082967B2 publication Critical patent/JP7082967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503341A 2016-07-22 2017-07-24 グルココルチコイド誘導性腫瘍壊死因子受容体(gitr)抗体及びその使用方法 Active JP7082967B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662365712P 2016-07-22 2016-07-22
US62/365,712 2016-07-22
US201662375634P 2016-08-16 2016-08-16
US62/375,634 2016-08-16
PCT/US2017/043504 WO2018018039A2 (en) 2016-07-22 2017-07-24 Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019524111A JP2019524111A (ja) 2019-09-05
JP2019524111A5 true JP2019524111A5 (enExample) 2020-09-03
JP7082967B2 JP7082967B2 (ja) 2022-06-09

Family

ID=59501631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503341A Active JP7082967B2 (ja) 2016-07-22 2017-07-24 グルココルチコイド誘導性腫瘍壊死因子受容体(gitr)抗体及びその使用方法

Country Status (13)

Country Link
US (2) US11046777B2 (enExample)
EP (1) EP3487884A2 (enExample)
JP (1) JP7082967B2 (enExample)
KR (1) KR102534568B1 (enExample)
CN (2) CN109689689B (enExample)
AU (2) AU2017300788B2 (enExample)
BR (1) BR112019001262A2 (enExample)
CA (1) CA3031194A1 (enExample)
IL (2) IL264376A (enExample)
MX (2) MX2019000963A (enExample)
RU (1) RU2019104896A (enExample)
SG (1) SG11201900500TA (enExample)
WO (1) WO2018018039A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7551499B2 (ja) * 2018-03-21 2024-09-17 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Fcバリアント組成物およびその使用方法
AU2018418224B2 (en) * 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
EP4225787A4 (en) * 2020-05-21 2024-10-23 Zydus Lifesciences Limited FC VARIANT AND PRODUCTION THEREOF
KR20230083316A (ko) * 2020-10-09 2023-06-09 더 호스피탈 포 식 칠드런 Sars-cov-2를 표적화하는 폴리펩티드, 및 관련 조성물 및 방법
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ スケール バイオロジー コーポレイション 形質転換された微生物によるメラニンの製造
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
JPH07500820A (ja) 1991-09-05 1995-01-26 ユニバーシティ オブ コネティカット ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005123774A2 (en) * 2004-06-15 2005-12-29 Erol Fikrig Antibodies to west nile virus polypeptides
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
CA2772613C (en) 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SMT202100116T1 (it) * 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
JP2017531427A (ja) 2014-10-03 2017-10-26 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド グルココルチコイド誘導腫瘍壊死因子受容体(gitr)抗体およびその使用法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
CA3049689A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling

Similar Documents

Publication Publication Date Title
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017531427A5 (enExample)
JP2015535691A5 (enExample)
JP2019524111A5 (enExample)
JP2020103301A5 (enExample)
JP2022159548A5 (enExample)
JP2020504076A5 (enExample)
JP2017114866A5 (enExample)
JP2018121657A5 (enExample)
JP2020525032A5 (enExample)
JP2018523493A5 (enExample)
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2012254092A5 (enExample)
JP2016505635A5 (enExample)
JP2017506067A5 (enExample)
JP2013227339A5 (enExample)
JP2020510422A5 (enExample)
JP2019507762A5 (enExample)
JP2019523221A5 (enExample)
JP2017149720A5 (enExample)
JP2013502913A5 (enExample)
JP2019525771A5 (enExample)
JP2019513777A5 (enExample)
JP2012519492A5 (enExample)
JP2014111644A5 (enExample)